Gastrointestinal Stimulators for Specialized Patient Populations

The inventive concept adapts implantable and non-invasive stimulators for gastrointestinal therapeutics to address specific needs in niche patient populations, such as those with spinal cord injuries, diabetes, or undergoing chemotherapy.

The original patent disclosed a system for gastrointestinal therapeutics using implantable and non-invasive stimulators. However, these solutions may not be suitable for patients with unique needs, such as those with spinal cord injuries, diabetes, or undergoing chemotherapy. The new inventive concept addresses these limitations by adapting the stimulators to cater to these specific patient populations.

The inventive concept comprises four specialized systems: (1) a miniaturized implant for treating gastrointestinal dysmotility in patients with spinal cord injuries, (2) a disposable miniaturized implant for expediting healing of surgical wounds in the GI tract, (3) a non-invasive transcutaneous stimulator for treating obesity in patients with a history of gastric bypass surgery, and (4) a system for treating nausea in patients undergoing chemotherapy. Each system incorporates sensors and mobile devices to monitor and adjust the stimulation parameters accordingly.

The new inventive concept introduces novel adaptations of the original stimulators to address specific needs in niche patient populations. The inventive step lies in the integration of sensors, mobile devices, and tailored stimulation parameters to cater to these unique populations.

Alternative embodiments could include variations in sensor types, stimulation protocols, and implantable or non-invasive designs. Additionally, the inventive concept could be adapted for use in other niche patient populations, such as those with neurological disorders or undergoing organ transplantation.

The inventive concept has significant commercial potential in the medical device industry, particularly in the areas of gastrointestinal therapeutics, neurology, and oncology. The target market includes hospitals, clinics, and medical research institutions serving niche patient populations.